CANCERNA Partners held a face-to-face meeting on September 5-6, 2022 meeting in Jerusalem
Breakthrough RNA-Based Anti-Cancer Immunotherapy Treatments Being Developed by Global Consortium led by the Hadassah Cancer Research Institute
HADASSAH AND DRUG GIANT MERCK LAUNCH MRNA INITIATIVE TO FIGHT CANCER
Immunyx Pharma Part of Global Consortium CanceRNA Developing RNA-based Cancer Vaccine
NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes
CANCERNA's 2nd Yearly Meeting: Driving Advancements in RNA Processing for Anti-Cancer Immunotherapy
CanceRNA Hosts Its 2nd Annual Meeting Focusing on RNA-Based Cancer Therapies at CRG, Barcelona
Welcome Letter from Prof. Carmo Fonseca, Chair of the RNA Horizons Conference Scientific Committee
Skip to content